Wichita was one of the 17 Community Hospital Oncology Programs (CHOPs) funded for implementation and which successfully mobilized community resources towards improving the care of the cancer patient. Initiated in 1983, the Wichita CCOP continues as an established successful program. It is a city-wide consortium of three major community hospitals with a total of 2,246 beds. The principal investigator, participating physicians administrative director, nurse data managers, and clerical personnel have been in place since program initiation, thereby offering the experience and expertise for continued successful program implementation. We have successfully entered over 100 patients each year on Southwest Oncology Group (SWOG) protocols and averaged 20 patients per year on Pediatric Oncology Group (POG) protocols. The Wichita CCOP plans to accrue 150.7 credits (142 patients) on therapeutic protocols and 79 credits (177 patients) on cancer control protocols using three research bases: Southwest Oncology Group; M.D. Anderson Hospital; and Pediatric Oncology Group.
The specific aims of the Wichita CCOP are: 1) to bring the benefits in medical care that result from participation in clinical trials to patients in Wichita and its surrounding catchment area of southern Kansas and northern Oklahoma - a patient population which would otherwise be unserved because its geographic location is remote from comprehensive cancer centers; 2) to provide continuing education to Wichita oncologists and others caring for cancer patients; 3) to increase accrual of patients on treatment protocols and thus reduce the time necessary to answer critical questions; 4) to provide an operational base for the extension of cancer control efforts in early detection, prevention screening, pretreatment evaluation, treatment, continuing care, and rehabilitation. With over 2,000 new cancer patients each year and our experience as a CHOP and CCOP, we have the necessary number of patients, expertise, and commitment to continue our successful therapeutic research effort and to expand into cancer control research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035431-09
Application #
3557776
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1983-09-15
Project End
1995-05-31
Budget Start
1992-06-01
Budget End
1993-05-31
Support Year
9
Fiscal Year
1992
Total Cost
Indirect Cost
Name
St. Francis Regional Medical Center
Department
Type
DUNS #
City
Wichita
State
KS
Country
United States
Zip Code
67214
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8

Showing the most recent 10 out of 307 publications